ETFs GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:10 2024-07-22 EDT 5-day change 1st Jan Change
1,524 GBX +0.13% Intraday chart for GSK plc +1.77% +5.12%

ETFs positioned on GSK plc

Name Weight AuM 1st Jan change Investor Rating
3.17% 11 M€ +0.83% -
3.15% 14 M€ +10.67% -
2.51% 7 M€ +8.56% -
1.96% 3 M€ -.--% -
0.88% 6 M€ -.--%
0.83% 2 M€ -.--% -
0.83% 2 M€ +9.19% -
0.77% 178 M€ +8.75%
0.75% 50 M€ +7.55%
0.55% 5 M€ -.--% -
0.50% 257 M€ +8.41%
0.40% 10 M€ -3.35% -
0.37% 29 M€ +8.37% -
0.37% 268 M€ +15.05% -
0.37% 204 M€ +13.33% -
0.37% 471 M€ +16.02%
0.32% 7 M€ +5.90% -
0.31% 36 M€ +6.91% -
0.29% 759 M€ +9.66%
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.24 GBP
Average target price
19.85 GBP
Spread / Average Target
+30.22%
Consensus